Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trials with Omico's Precision Oncology Screening Platform (PrOSPeCT), Australia's largest cancer genomics program. The partnership aims to improve trial planning, site selection, and patient recruitment, thereby expanding opportunities for Australian patients to participate in targeted cancer research. This initiative supports faster identification of suitable patients and advances personalized cancer treatment development.
Fortrea Holdings Inc and Omico's partnership in biomarker-driven cancer drug development is noted alongside Pluang's health sector market data. For readers following the health sector, here is Pluang's market snapshot as of Oct 24, 2026 00:21 WIB: out of 150 priced US health stocks, 47 rose and 103 fell. Notable movers include BioNano Genomics Inc (BNGO) at USD 1.14 with a -3.81% change and a typical hold time of 51 days, Guardant Health Inc (GH) at USD 169.12 with a +3.79% change and a typical hold time of 4 days, and Tilray Brands Inc (TLRY) at USD 2.82 with a -3.75% change and a typical hold time of 31 days.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
Greg Abel highlighted that every one percentage point increase in the profit margin of BNSF Railway translates to approximately $230 million in additional cash flow for Berkshire Hathaway. This underscores the significant impact BNSF's operational ef...
